Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Daré Bioscience, Inc. to Present at the Dawson James Small Cap Growth Conference
SAN DIEGO , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that John Fair , Chief Business Officer, will present at the Dawson James Securities 4th Annual Small Cap Growth Conference on Tuesday, October
View HTML
Toggle Summary Daré Announces Two Late-Breaking Abstracts to be Presented at the American Association of Pharmaceutical Scientists (AAPS) in Washington D.C.
SAN DIEGO , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will be presenting two late-breaking abstracts at the upcoming Association of Pharmaceutical Scientists (AAPS) meeting taking place
View HTML
Toggle Summary Daré to Host Third Quarter 2018 Financial Results Conference Call and Webcast
SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it will host a conference call and live webcast at 8:30 a.m. Eastern Time on Tuesday, November 13, 2018 , to provide a corporate update and
View HTML
Toggle Summary Daré Bioscience Provides Business Update and Announces Third Quarter Financial Results
SAN DIEGO , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s biopharmaceutical company, today provided a business update and announced financial results for the three and nine months ended September 30, 2018.
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Enrollment in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it is currently enrolling
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Initiation of Content Validity Study for Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Sildenafil Cream, 3.6% has the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder SAN DIEGO , Nov. 29, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc . (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, and Strategic Science & Technologies, LLC (SST), a
View HTML
Toggle Summary Daré Bioscience, Inc. Announces Licensing and Global Rights to Novel Phase III Product Candidate for the Treatment of Bacterial Vaginosis
Bacterial vaginosis affects nearly 20 million women in the U.S. every year SAN DIEGO , Dec. 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in clinical-stage women’s health innovation, today announced that it has entered into definitive agreements with Hammock
View HTML
Toggle Summary Daré Bioscience Provides Update for Investors on Development Programs and Anticipated 2019 Milestones
Key anticipated 2019 clinical milestones: Topline results of Ovaprene® PCT clinical trial Initiation of at-home portion of Sildenafil Cream, 3.6% Phase 2b Initiation of pivotal Phase 3 study of DARE-BV1 SAN DIEGO , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc.
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the 2019 BIO CEO & Investor Conference
SAN DIEGO , Feb. 05, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson , President and Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference on Tuesday, February 12, 2019 at 9:45 a.m.
View HTML
Toggle Summary Daré Bioscience, Inc. to Present at the 16th Annual BIO Asia International Conference
SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson , President and Chief Executive Officer, will present at the 16th Annual BIO Asia International Conference on Tuesday, March 5, 2019 at
View HTML